Genzyme/Sanofi-Aventis
On February 16 2011, Genzyme Corporation (Nasdaq: GENZ) confirmed a definitive agreement to be acquired by Sanofi-aventis (NYSE: SNY) for $74.00 per share in cash, or approximately $20.1 billion, plus one Contingent Value Right.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
-
BioMarin Announces Record Revenues in First Quarter 2022
-
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
-
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
-
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
-
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
-
BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
-
BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
-
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
-
BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
-
BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
-
BioMarin Announces Third Quarter 2019 Financial Results
-
BioMarin Announces Second Quarter 2019 Financial Results
-
Jefferies Trims PT on BioMarin Pharma (BMRN), Keeps 'Buy'
-
BioMarin Announces Pricing of Public Offering of Common Stock
-
BioMarin Announces Public Offering of Common Stock
-
BioMarin to Present at the Barclays Global Healthcare Conference in Miami
-
BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results
-
BioMarin to Present at the Cowen Healthcare Conference in Boston
-
BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome
-
BioMarin (BMRN) May Draw Interest Following Recent FDA Panel Vote (PFE) (RHHBY)
-
Biotech M&A Will Be In Focus in 2012 - Goldman
-
Jefferies Cuts Estimate & Raises Price Target on BioMarin Pharmaceutical (BMRN), Maintains Buy Rating
-
Morgan Joseph Upgrades BioMarin (BMRN) to Buy, A Genzyme Deal Could Highlight Attractiveness
